Neuronal [3H]benzodiazepine binding and levels of GABA, glutamate, and taurine are normal in Huntington's disease cerebellum.
Alterations in one subunit of the proposed GABA receptor complex, namely, the GABA receptor, have been observed in Huntington's disease cerebellum. We measured binding to a second subunit, the benzodiazepine binding site, in the autopsied cerebellum of 12 patients dying with adult-onset Huntington's disease. Neuronal benzodiazepine ([3H]flunitrazepam) binding density (Bmax) and affinity in cerebellar cortex of the Huntington's disease patients were not significantly different from control values. Similarly, maximal GABA stimulation of benzodiazepine binding was normal in the Huntington's disease cerebellum. In addition, no significant changes were observed in the concentrations of GABA, glutamate, and taurine in cerebellar cortex, nor of GABA in the dentate nucleus.
D000596:Amino Acids / Q000378:metabolism*; D002531:Cerebellum / Q000378:metabolism*; D005445:Flunitrazepam / Q000378:metabolism; D005971:Glutamates / Q000378:metabolism; D018698:Glutamic Acid; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D008875:Middle Aged; D009474:Neurons / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000378:metabolism*; D011963:Receptors, GABA-A; D013654:Taurine / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000596:Amino Acids; D005971:Glutamates; D011956:Receptors, Cell Surface; D011963:Receptors, GABA-A; D013654:Taurine; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam; D006220:Haloperidol